Evidence from clinical studies and basic research has shown a strong correlation between Alzheimer’s disease (AD) and type 2 diabetes. Tau, a neuronal microtubule-associated protein, is hyperphosphorylated and aggregated into neurofibrillary tangles in the AD brain. However, the expression of tau in pancreas is under debate.
Objective:
We determined the expression of tau in mouse pancreas.
Methods:
We used western blots, immunoprecipitation, and immunohistochemical staining to analyze pancreatic expression of tau in mice.
Results:
We found that neither total tau nor phosphorylated tau was detectable in the mouse pancreas by western blots. Immunostaining with pan tau antibodies R134d and Tau-5 revealed bright and dense varicosities in the pancreatic islets and the exocrine pancreas. These varicosities were immunoreactive to synapsin 1, a presynaptic marker which can outline autonomic nerve profiles in pancreas, exhibiting complete colocalization with tau. Importantly, endocrine cells in islets did not exhibit specific immunoreactivity to any of pan tau antibodies tested, nor did the exocrine cells.
Conclusion:
In the mouse pancreas, we found that tau is exclusively expressed in autonomic nerve fibers, but there is no detectable expression in endocrine cells in the islet.
ModyN, AgouniA, McIlroyGD, PlattB, DelibegovicM (2011) Susceptibility to diet-induced obesity and glucose intolerance in the APP (SWE)/PSEN1 (A246E) mouse model of Alzheimer’s disease is associated with increased brain levels of protein tyrosine phosphatase 1B (PTP1B) and retinol-binding protein 4 (RBP4), and basal phosphorylation of S6 ribosomal protein. Diabetologia54, 2143–2151.
5.
WijesekaraN, GoncalvesRA, AhrensR, De FeliceFG, FraserPE (2018) Tau ablation in mice leads to pancreatic beta cell dysfunction and glucose intolerance. FASEB J32, 3166–3173.
6.
BharadwajP, WijesekaraN, LiyanapathiranaM, NewsholmeP, IttnerL, FraserP, VerdileG (2017) The link between type 2 diabetes and neurodegeneration: roles for amyloid-beta, amylin, and tau proteins. J Alzheimers Dis59, 421–432.
7.
KanaanNM, MorfiniGA, LaPointeNE, PiginoGF, PattersonKR, SongY, AndreadisA, FuY, BradyST, BinderLI (2011) Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of al phosphotransferases. J Neurosci31, 9858–9868.
8.
AustinTO, MatamorosAJ, FriedmanJM, FriedmanAJ, NacharajuP, YuW, SharpDJ, BaasPW (2017) Nanoparticle delivery of fidgetin siRNA as a microtubule-based therapy to augment nerve regeneration. Sci Rep7, 9675.
9.
Grundke-IqbalI, IqbalK, QuinlanM, TungYC, ZaidiMS, WisniewskiHM (1986) Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem261, 6084–6089.
10.
Grundke-IqbalI, IqbalK, TungYC, QuinlanM, WisniewskiHM, BinderLI (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A83, 4913–4917.
11.
GuY, OyamaF, IharaY (1996) Tau is widely expressed in rat tissues. J Neurochem67, 1235–1244.
12.
MajM, GartnerW, IlhanA, NeziriD, AttemsJ, WagnerL (2010) Expression of tau in insulin-secreting cells and its interaction with the calcium-binding protein secretagogin. J Endocrinol205, 25–36.
13.
MiklossyJ, QingH, RadenovicA, KisA, VilenoB, LaszloF, MillerL, MartinsRN, WaeberG, MooserV, BosmanF, KhaliliK, DarbinianN, McGeerPL (2010) Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. Neurobiol Aging31, 1503–1515.
14.
WijesekaraN, AhrensR, SabaleM, WuL, HaK, VerdileG, FraserPE (2017) Amyloid-beta and islet amyloid pathologies link Alzheimer’s disease and type 2 diabetes in a transgenic model. FASEB J31, 5409–5418.
15.
MajM, HoermannG, RasulS, BaseW, WagnerL, AttemsJ (2016) The microtubule-associated protein tau and its relevance for pancreatic beta cells. J Diabetes Res2016, 1964634.
16.
TischlerAS (2002) Chromaffin cells as models of endocrine cells and neurons. Ann N Y Acad Sci971, 366–370.
17.
TuckerKL, MeyerM, BardeYA (2001) Neurotrophins are required for nerve growth during development. Nat Neurosci4, 29–37.
18.
OddoS, CaccamoA, ShepherdJD, MurphyMP, GoldeTE, KayedR, MetherateR, MattsonMP, AkbariY, LaFerlaFM (2003) Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron39, 409–421.
19.
MiaoJ, ShiR, LiL, ChenF, ZhouY, TungYC, HuW, GongCX, IqbalK, LiuF (2019) Pathological tau from Alzheimer’s brain induces site-specific hyperphosphorylation and SDS- and reducing agent-resistant aggregation of tau in vivo. Front Aging Neurosci11, 34.
20.
LiL, JiangY, HuW, TungYC, DaiC, ChuD, GongCX, IqbalK, LiuF (2019) Pathological alterations of tau in Alzheimer’s disease and 3xTg-AD mouse brains. Mol Neurobiol56, 6168–6183.
21.
Rodriguez-DiazR, AbdulredaMH, FormosoAL, GansI, RicordiC, BerggrenPO, CaicedoA (2011) Innervation patterns of autonomic axons in the human endocrine pancreas. Cell Metab14, 45–54.
22.
VandalM, WhitePJ, ChevrierG, TremblayC, St-AmourI, PlanelE, MaretteA, CalonF (2015) Age-dependent impairment of glucose tolerance in the 3xTg-AD mouse model of Alzheimer’s disease. FASEB J29, 4273–4284.
23.
PetryFR, PelletierJ, BrettevilleA, MorinF, CalonF, HebertSS, WhittingtonRA, PlanelE (2014) Specificity of anti-tau antibodies when analyzing mice models of Alzheimer’s disease: problems and solutions. PLoS One9, e94251.
24.
ErcanE, EidS, WeberC, KowalskiA, BichmannM, BehrendtA, MatthesF, KraussS, ReinhardtP, FulleS, EhrnhoeferDE (2017) A validated antibody panel for the characterization of tau post-translational modifications. Mol Neurodegener12, 87.
